Premier Biomedical Announces Intended $6 Million Investment by Brazilian Joint Venture Partner, Auramedi, to Manufacture, Market and Distribute Premier’s New Technology Products
EL PASO, Texas–(BUSINESS WIRE)–Premier Biomedical, Inc.(OTCQB:”BIEI”)
a biotech research company focused on discovering, developing, and
commercializing medical treatments for a wide range of diseases in
humans, including innovative therapies for breast cancer, as well as for
fibromyalgia, neuropathy, atherosclerosis and muscular dystrophy
confirmed today that its planned Brazilian joint venture partner,
Auramedi Farmacêutica, Ltd., has announced its intention to invest up to
BRL$25 Million (USD$ 6 Million) to establish facilities for the
manufacture, distribution and sale of Premier Biomedical drugs and other
treatments in Brazil and South America.
A source inside Auramedi, familiar with the matter, has confirmed the
intentions of the Brazilian company to develop the JV, and the
possibility of accelerating the investment, once the JV partnership is
consummated. “Auramedi’s master plan established that we would invest
from 20 to 25 Million Brazilian Real over the next five years, to set up
our facility. However, with the advent of the joint venture, this amount
could be invested earlier, due to the confidence we have regarding the
success potential of this endeavor.” the source said.
Premier is working, with Auramedi’s support, on investigations to apply
Premier’s extracorporeal technology toward finding a cure for the Zika
and Dengue viruses.
William A. Hartman, President and CEO of Premier Biomedical stated, “We
are extremely pleased with the progress and interest Auramedi has shown
in the development and success of this Brazilian joint venture. Their
top management has participated in regular meetings with Premier, and
continues to do so. We are confident the remaining issues in
establishing the JV will be resolved in short order.”
Contact William Hartman at (724) 633-7033, PR@premierbiomedical.com.
About Premier Biomedical, Inc.
Premier
Biomedical, Inc. (OTCQB: BIEI)
is a research-based company that intends to discover and develop medical
treatments for a wide range of diseases in humans. Premier has obtained,
via license agreements, the technology behind three granted U.S.
patents, multiple pending provisional patents, and a PCT Europe National
Patent. Founded in 2010, Premier has partnered with the Department of
Defense with Center of Expertise at the William Beaumont Army Medical
Center. The company’s R&D efforts are centered in El Paso, TX. The
Company is a fully-reporting issuer whose common stock trades on the
OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker
symbol “BIEI“.
For more information, visit our website http://www.premierbiomedical.com/
About Auramedi Farmacêutica Ltda
Auramedi (http://www.auramedi.com/)
is a Brazilian pharmaceutical company, dedicated to bringing to the
Brazilian health care market innovation and increment in each of its
products. Auramedi is highly committed to finding solutions and
treatments to achieve the best result for patients, prescribers,
caregivers, consumers and all those who face challenges in their health
or well-being, providing access to the best medical and pharmaceutical
treatments science are able to provide.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as
defined in the Private Securities Litigation Reform Act of 1995).
Premier Biomedical, Inc. cautions that statements, and assumptions made
in this news release constitute forward-looking statements and makes no
guarantee of future performance. Forward-looking statements are based on
estimates and opinions of management at the time statements are made.
These statements may address issues that involve significant risks,
uncertainties, estimates made by management. Actual results could differ
materially from current projections or implied results. Premier
Biomedical, Inc. undertakes no obligation to revise these statements
following the date of this news release.
Contacts
Premier Biomedical, Inc.
William Hartman, 724-633-7033
PR@premierbiomedical.com.